Feb 5, 2024
Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send...
Feb 5, 2024
Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send...
Sep 29, 2022
Jason Matuszewski, Chief Executive Officer and Chairman of the Board, and Andrew Van Vurst, Chief Operating Officer of BioStem Technologies have a vision to change the paradigm on the use of perinatal tissue for advanced wound care. Their initial target is complex wounds in the lower extremity region, specifically...
Sep 29, 2022
Jason Matuszewski, Chief Executive Officer and Chairman of the Board, and Andrew Van Vurst, Chief Operating Officer of BioStem Technologies have a vision to change the paradigm on the use of perinatal tissue for advanced wound care. Their initial target is complex wounds in the lower extremity region, specifically...
Mar 29, 2022
Craig Parker is the CEO of Surrozen, experts in the Wnt pathway which is one of the fundamental pathways that help to establish the structure of organs, renewal of stem cells, and recovery from injury. This is a story of discovering the right combination of their tissue-specific approach and the right molecules to...